[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laval University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":658},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,49,79,110,142,164,194,219,244,265,287,310,333,354,382,410,441,471,492,511,534,563,583,603,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641711","home-based-exercise-therapy-in-patients-with-moderate-to-severe-peripheral-artery-disease-100641711",false,"NCT07655206","Home-based Exercise Therapy in Patients With Moderate to Severe Peripheral Artery Disease","Effectiveness of a Home-based Cardiovascular Rehabilitation Program Compared With Standard Care in Patients With Moderate to Severe Peripheral Artery Disease: a Pilot Randomized Controlled Trial (PILOT-PAD-CYCLE)","PILOT-PADCYCLE","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Moderate-to-severe peripheral arterial disease defined by at least one of the following:\n\nABI \\\u003C 0.6 Ankle systolic pressure \\\u003C 70 mmHg Toe systolic pressure \\\u003C 40 mmHg Toe-brachial index \\\u003C 0.4\n\n* With or without lower limb wound\n* Declined referral to an in-person supervised exercise therapy program\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Lower limb revascularization within the previous 30 days\n* Planned revascularization during the first 12 weeks of the study\n* Unable to use a portable pedal exerciser\n* Unable to perform a 6-minute walk test\n* Medically unstable according to the treating clinical or rehabilitation team\n* Participation in a cardiovascular rehabilitation program within the previous year","ALL","18 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","Peripheral arterial disease (PAD) is a chronic atherosclerotic condition associated with impaired mobility, reduced quality of life, cardiovascular events, and risk of lower limb amputation. Although supervised exercise therapy (SET) is recommended for symptomatic PAD, access and adherence remain limited, particularly among patients with moderate-to-severe disease or chronic limb-threatening ischemia (CLTI).\n\nThe PILOT-PAD-CYCLE study is a prospective, single-center, pilot randomized controlled trial designed to evaluate the feasibility, acceptability, and preliminary efficacy of a 12-week home-based exercise therapy (HET) program using a portable pedal exerciser in adults with moderate-to-severe PAD, including CLTI, with or without foot wounds.\n\nTwelve participants will be randomized 1:1 to either HET plus standard care or standard care alone. The intervention includes individualized exercise prescription, remote supervision by a kinesiologist, cardiovascular education, and follow-up over 12 weeks. Outcomes include feasibility and acceptability metrics, 6-minute walk test distance, vascular perfusion indices, quality of life, and cardiovascular events up to 6 months.\n\nThis pilot trial aims to generate feasibility data and preliminary efficacy estimates to support the development of a future multicenter randomized controlled trial.",[28],"Peripheral Artery Disease",[28,30,31,32,33,34,35,36],"Chronic Limb-Threatening Ischemia","Home-Based Exercise Therapy","Cardiovascular Rehabilitation","Pedal Exerciser","Peripheral Vascular Disease","Exercise Therapy","Randomized Controlled Trial","RECRUITING","2026-06-23",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":38,"type":41},{"date":44,"type":22},"2027-05-01",{"name":46,"class":47},"Laval University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100641118","immersive-virtual-reality-for-older-adults-in-long-term-care-settings-100641118","NCT07658287","Immersive Virtual Reality for Older Adults in Long-Term Care Settings","Use of Immersive Virtual Reality in Long-Term Care Facilities and Seniors' Homes in Quebec","VR-LTC","Inclusion Criteria:\n\nFor resident participants:\n\n* Resident of a participating long-term care facility, seniors' home, or alternative seniors' home in the Chaudière-Appalaches or Capitale-Nationale regions of Quebec\n* Aged 60 years or older\n* Able to understand French or English\n* Able to provide informed consent or assent, or have consent provided by a legally authorized representative or person authorized to consent\n* Mild to moderate cognitive impairment or neurocognitive disorder\n* Normal or corrected vision and hearing\n\nFor staff participants:\n\n* Regularly works with at least one resident participating in Phase 3\n* Has completed the revised virtual reality training provided by Super Splendide and\u002For Martine Bordeleau\n\nExclusion Criteria:\n\nFor resident participants:\n\n* Recurrent migraines\n* Epilepsy\n* Traumatic brain injury during the past year\n* Glaucoma or recovery from eye surgery\n* Diagnosed uncontrolled epilepsy\n* Diagnosed severe vertigo\n* Severe hearing impairment without a corrective hearing device\n* Significant visual impairment that would prevent use of a virtual reality headset\n* Motion sickness that would prevent use of a virtual reality headset\n* Any health condition that restricts movement or prevents safe participation, such as a significant reduction in neck or upper-limb range of motion","60 Years",{"count":59,"type":22},36,[25],"The goal of this clinical trial is to learn if an immersive virtual reality mindfulness meditation program is feasible and acceptable for older adults living in long-term care settings in Quebec who have mild to moderate neurocognitive disorder. It will also learn about the safety and potential effects of the program on well-being.\n\nThe main questions it aims to answer are:\n\n* Is the virtual reality mindfulness meditation program feasible and acceptable for residents and staff in long-term care settings?\n* Does the adapted version of the program show potential benefits for well-being, including depression, anxiety, quality of life, mindfulness, pain, and loneliness?\n* What practical challenges, user experiences, and side effects, such as cybersickness, occur during the program?\n\nResearchers will compare the original Toujours Dimanche virtual reality mindfulness meditation program, an adapted version of Toujours Dimanche designed for older adults with mild to moderate neurocognitive disorder, and standard care alone to see if the adapted program is feasible, acceptable, and potentially helpful.\n\nParticipants will:\n\n* Take part in up to 8 virtual reality mindfulness meditation sessions over 4 weeks, if assigned to a virtual reality group\n* Complete questionnaires before and after the 4-week study period\n* Share feedback about their experience, when possible\n* Be observed by staff or research team members to document feasibility, acceptability, user experience, and safety",[63,64],"Cognitive Impairment","Long-term Care Centres for Old Adults Users",[66,67,68,69,63],"Virtual Reality","Mindfulness Meditation","Long-Term Care","Older Adults","NOT_YET_RECRUITING","2026-06-16",{"date":73,"type":41},"2026-06-18",{"date":75,"type":22},"2026-06-15",{"date":77,"type":22},"2027-06-15",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100642654","virtual-reality-for-pain-and-well-being-in-older-adults-100642654","NCT07607899","Virtual Reality for Pain and Well-Being in Older Adults","Moving Without Fear or Pain: Use of Immersive Virtual Reality to Reduce Pain and Improve Well-Being in Older Adults","VitaMove","Inclusion Criteria:\n\n* Age 65 years or older\n* Able to understand and communicate in French\n* Chronic pain lasting 6 months or longer\n* Average pain intensity of 3 or greater on a 0-10 Numeric Rating Scale during the week prior to enrollment\n* Score greater than 25 on the 11-item Tampa Scale of Kinesiophobia (TSK-11)\n* No neurocognitive impairment (Mini-Mental State Examination \\[MMSE\\] ≥ 24), or mild neurocognitive impairment (MMSE 18-24) with preserved capacity to consent (University of California Brief Assessment of Capacity to Consent \\[UBACC\\] score ≥ 12)\n* Normal or corrected-to-normal visual acuity\n\nExclusion Criteria:\n\n* Severe motion sickness or intolerance that would prevent safe use of a virtual reality headset (experimental group only)\n* Medical condition that would prevent safe participation in rehabilitation activities\n* Presence of open wounds or infection at painful or contralateral sites","65 Years",{"count":89,"type":22},24,[25],"Chronic pain is common among adults aged 65 and older and can reduce mobility, independence, mood, and quality of life. Many older adults also develop a fear of movement because they worry that physical activity will increase their pain or cause injury. This fear can lead to reduced activity, physical deconditioning, and further loss of independence. This study aims to evaluate the feasibility, acceptability, and potential impact of Moving Without Fear or Pain, a program combining structured pain education (Empowered Relief) with immersive virtual reality rehabilitation to gradually reintroduce movement in a safe and engaging way. Empowered Relief is a single-session, two-hour online pain education class delivered by a trained health professional. It explains how chronic pain affects the brain and nervous system and teaches strategies to calm the nervous system, manage pain flare-ups, reduce pain-related worry and catastrophizing, and increase confidence in movement and daily activities.\n\nThe virtual reality intervention includes up to eight individualized sessions over approximately one month. Sessions last 5 to 30 minutes and are supervised by a trained clinician. Participants wear a virtual reality headset and are immersed in calming or engaging environments, such as nature settings. Depending on their comfort and abilities, sessions may begin with passive guided motor imagery and progress to active movement within interactive virtual environments. Some applications allow participants to control movement in the virtual world through gentle physical activity, such as stepping or upper-body movement. The intervention is personalized to each participant's physical capacity, preferences, and rehabilitation goals. The aim is to reduce fear of movement, increase confidence, and promote safe re-engagement in physical activity. In this pilot randomized controlled trial, 24 older adults with chronic pain will be randomly assigned to one of two groups: 1) Experimental Group: Participants will receive the Empowered Relief pain education course, usual care, and up to eight immersive virtual reality rehabilitation sessions. 2) Control Group: Participants will receive the Empowered Relief pain education course and usual care, without virtual reality sessions. The findings will inform a larger future study.",[93,94],"Chronic Pain","Kinesiophobia (Fear of Movement)",[93,69,96,97,98,99,100,101,102],"Kinesiophobia","Fear of Movement","Empowered Relief","Biopsychosocial Model","Motor Imagery","Virtual Reality Rehabilitation","Non-Pharmacological Pain Management","2026-06-12",{"date":71,"type":41},{"date":106,"type":22},"2026-06",{"date":108,"type":22},"2027-03",{"name":46,"class":47},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":48},"100638337","virtual-reality-relaxation-for-insomnia-100638337","NCT07630532","Virtual Reality Relaxation for Insomnia","Virtual Reality Relaxation Intervention for Individuals With Insomnia","Inclusion Criteria:\n\n* Aged between 25 and 50 years\n* Experiencing difficulty initiating sleep, maintaining sleep, or early-morning awakenings at least three times per week for a minimum of three months\n* Residing within a 25-km radius of Université Laval\n\nExclusion Criteria:\n\n* Diagnosis of serious medical conditions (e.g., cancer, neurological disorders, chronic pain) or major psychiatric disorders\n* Conditions that could be exacerbated by virtual reality devices (e.g., epilepsy, eye disorders, dizziness, balance disorders)\n* Adverse effects related to virtual reality use (e.g., dizziness, nausea)\n* Currently using prescription or over-the-counter sleep aids\n* Engaged in night shifts or rotating shift work","25 Years","50 Years",{"count":120,"type":22},30,[25],"The goal of this clinical trial is to evaluate the feasibility, acceptability, and preliminary effects of a virtual reality (VR) relaxation intervention among adults aged 25 to 50 with insomnia disorder.\n\nThe main questions this study aims to address are:\n\n* Is a VR relaxation intervention feasible to implement and acceptable for individuals with insomnia?\n* Does the intervention reduce pre-sleep cognitive and somatic arousal?\n* Does the intervention improve sleep quality and sleep depth?\n* Can the intervention enhance overall sleep health and reduce symptoms of insomnia, anxiety, and depression?\n* Are these potential benefits maintained at a 3-month follow-up?\n\nParticipants will be randomly assigned to either the intervention group or a waitlist control group. Researchers will compare outcomes between groups to evaluate the impact of the intervention.\n\nParticipants will:\n\n* Complete online questionnaires at three time points (baseline, post-intervention, and 3-month follow-up) assessing sleep health, pre-sleep arousal, and symptoms of insomnia, anxiety, and depression\n* Take part in an in-person diagnostic interview at Université Laval to assess sleep and mental health status\n* Complete a daily online sleep diary for 8 weeks (2 weeks baseline, 4 weeks intervention, and 2 weeks post-intervention)\n* Engage in a 15-minute VR-guided meditation session each evening at home for 4 weeks\n* Wear a portable sleep monitor at home for 8 nights (4 nights baseline and 4 nights post-intervention)\n* Complete an acceptability questionnaire following the intervention",[124],"Insomnia Disorder",[126,127,128,129,130,131,132,133],"Insomnia disorder","Hyperarousal","Virtual reality","Polysomnography","Sleep quality","Guided meditation","Slow breathing","Sleep health","2026-06-01",{"date":136,"type":41},"2026-06-05",{"date":138,"type":41},"2025-09-01",{"date":140,"type":22},"2027-09",{"name":46,"class":47},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":48},"100639949","right-ventricular-function-and-respiratory-acidosis-after-cardiac-surgery-100639949","NCT07619274","Right Ventricular Function and Respiratory Acidosis After Cardiac Surgery","Inclusion Criteria:\n\n* Previously included and complete study NCT05886413 or NCT06826794\n\nExclusion Criteria:\n\n* Absence of one or more of the following hemodynamic measurements: systolic or diastolic pulmonary artery pressure, central venous pressure, cardiac output\n* Absence of arterial blood gas on arrival to the intensive care unit",{"count":149,"type":22},220,"OBSERVATIONAL","Right heart dysfunction remains a frequent cause of morbidity and mortality after cardiac surgery. Respiratory acidosis, particularly when accompanied by hypoxemia, plays a significant role in right heart failure, primarily by increasing right ventricular afterload through pulmonary vasoconstriction and elevated pulmonary arterial pressures. This phenomenon leads to increased right ventricular workload, causing dilation, decreased contractility, and ultimately right heart failure. The study aims to evaluate the effect of respiratory acidosis on right ventricular function after cardiac surgery.",[153,154,155,156],"Respiratory Acidosis in ICU Patients","Right Ventricular (RV) Dysfunction","Hemodynamic Changes","Mechanical Ventilation","2026-05-28",{"date":134,"type":41},{"date":160,"type":22},"2026-05",{"date":162,"type":22},"2026-10",{"name":46,"class":47},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":173,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":48},"100637190","effect-of-dairy-protein-yogourt-vs-plant-based-yogourt-on-body-weight-body-composition-bone-health-and-gut-microbiota-100637190","NCT07578103","Effect of Dairy Protein Yogourt vs Plant-based Yogourt on Body Weight, Body Composition, Bone Health and Gut Microbiota","A New Focus on Protein and the Gut Microbiota to Explain Health Benefits of Dairy Foods","PROYO","Inclusion Criteria:\n\n* Postmenopausal women (absence of menstruation for at least 1 year and FSH \\> 40 IU\u002FL)\n* BMI between 27.0 and 39.9 kg\u002Fm²\n* Sedentary or moderately active\n\nExclusion Criteria:\n\n* Body weight change greater than 5 kg in the 3 months preceding the study\n* Currently dieting or following specific dietary patterns\n* Previous or planned bariatric surgery\n* Food allergies or intolerances (particularly dairy proteins and lactose)\n* Serious or problematic health conditions (e.g., renal insufficiency, diabetes, Cushing's disease, Paget's disease, parathyroid disorders, inflammatory bowel disease, uncontrolled thyroid disease, etc.)\n* Fracture within the past year\n* Hormone therapy\n* Medications affecting bone metabolism (e.g., osteoporosis treatments, anti-estrogen therapy for breast cancer, epilepsy treatments)\n* Antibiotic use within the 6 months preceding the study\n* Use of probiotic supplements (capsules)\n* More than two alcoholic drinks per day\n* Smoking\n* Drug abuse",true,"FEMALE","40 Years",{"count":176,"type":22},75,[25],"The consumption of an adequate quantity of protein in the diet is essential to maintain a healthy body composition and functioning. It is also well established that all proteins are not equal regarding their ability to promote health benefits. Recently, we have innovated in that matter by showing that under the context of high intake of dietary fat, the dairy protein casein was more effective than a mix of proteins representative of a western diet to prevent body weight gain and insulin resistance. This was explained in part by modifications of the gut microbiota. This finding represents the main conceptual basis of the present research program that is aimed to determine the impact of dairy protein from yogurt compared to a plant-based equivalent on body composition indicators including muscle mass and bone mineral density, in relation to the profile of the gut microbiota, the production of newly discovered protein-derived metabolites, and markers of metabolic health. This program will include a human and an animal component requiring the testing of these variables before and after a standardized intervention. The human component will be a clinical study consisting of a 12-week diet-based weight loss intervention in postmenopausal overweight women being randomly assigned to one of the three following groups: yogurt, plant-based yogurt, or kept on diet without supplements. The animal experimentation will permit to causally determine the implication of the gut microbiota in the protein effects following transfer of the human bacteria to germ free mice and validate the benefits seen in humans. It is anticipated that these two complementary investigative approaches will allow a thorough documentation of the impact of fermented dairy protein on body composition and functioning, a better understanding of the underlying mechanisms, and the identification of new biomarkers to better appreciate related health benefits.",[180,181,182,183,184,185],"Body Composition Changes","Body Weight Change","Metabolic Health","Bone Metabolism","Bone Health","Gut Microbiota","2026-05-05",{"date":188,"type":41},"2026-05-11",{"date":190,"type":41},"2023-11-01",{"date":192,"type":22},"2026-12-31",{"name":46,"class":47},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":48},"100621146","effectiveness-of-motorised-lumbar-support-for-non-specific-low-back-pain-100621146","NCT07366827","Effectiveness of Motorised Lumbar Support for Non-specific Low Back Pain","Effectiveness of a Motorized Lumbar Support for Non-specific Low Back Pain: A Randomized Controlled Trial","Inclusion Criteria\n\n* Adults between 18 and 65 years old with non-specific low back pain.\n* Average pain level of ≥3 out of 10 during the previous week.\n* Pain-related disability ≥10% at ODI.\n* Pain relief must be present during manual traction, measured by a moderate improvement (+3) on a global rating of change scale (anchors: -7 to +7).\n\nExclusion Criteria:\n\n* Specific cause of low back pain (e.g., fracture, cancer, spinal stenosis, severe spondylolisthesis)\n* Presence of neuropathic pain (leg or back of 4 at the DN4).\n* Pregnancy.\n* Body mass index \\> 32.\n* Waist size between 74 and 115 cm.\n* Respiratory and circulatory conditions.\n* Osteoporosis.\n* Paraplegia and hemiplegia.\n* Abdominal wounds at the site of the orthosis.\n* Rib or pelvic fractures less than 3 months.\n* Presence of electronic medical device.",{"count":202,"type":22},70,[25],"Low back pain (LBP) represents a common musculoskeletal conditions worlwide, causing substantial disability and economic burden. While traditional semi-rigid lumbar supports are commonly prescribed to alleviate LBP symptoms, their effectiveness remains limited by their static mechanical properties and lack of adaptability to movement patterns. Motorized lumbar support offer a novel approach by allowing the application of controlled decompressive forces while maintaining functional mobility. This experimental study aims to compare the effectiveness between a motorized lumbar support and a standard semi-rigid support in adults with non-specific LBP. Seventy adults with non-specific low back pain (LBP) will be recruited. Primary outcomes (pain intensity and physical functioning \\[daily average\\]) will be collected daily, while secondary outcomes (average pain intensity over the last week, pain-related disability, etc.) will be assessed at baseline, 3 and 9 weeks after randomization.",[206],"Non-specific Low Back Pain",[208,209,210],"non-specific low back pain","motorized lumbar support","standard lumbar support","2026-04-22",{"date":213,"type":41},"2026-04-24",{"date":215,"type":41},"2026-02-16",{"date":217,"type":22},"2028-09-01",{"name":46,"class":47},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":48},"100630762","identification-of-objective-metabolomics-based-biomarkers-of-yogurt-consumption-100630762","NCT07491887","Identification of Objective Metabolomics-based Biomarkers of Yogurt Consumption","YOGBIO","Inclusion criteria:\n\n* age: 18-70 years;\n* BMI: 18-40 kg\u002Fm²;\n* willingness to consume plain yogurt daily for 3 weeks;\n* for coffee\u002Ftea consumers, willingness to consume these beverages without added milk, cream or sugar for 4 weeks.\n\nExclusion criteria:\n\n* lactose intolerance; blood donation within 2 months; severe chronic illness or ongoing treatment for conditions such as infections, autoimmune diseases, cancer, type 2 diabetes, Crohn's disease, celiac disease, hepatic or renal diseases;\n* history of severe cancer, cardiovascular disease or bariatric surgery;\n* unstable body weight for 3 months;\n* illicit drug use or alcoholism; tobacco\u002Fcannabis smoking\u002Fvaping (ensuring no day-to-day fluctuations and objective reporting of consumption is too complex);\n* allergies or aversions to components of the diets.","70 Years",{"count":228,"type":22},16,[25],"Substantial evidence links yogurt consumption to a lower risk of type 2 diabetes (T2D). However, the existing evidence is derived exclusively from prospective cohort studies relying on self-reported dietary questionnaires, which-despite being validated-are subject to random and systematic errors that may compromise evidence quality and hinder regulatory approval.\n\nThe project aims to discover and validate biomarkers of yogurt intake.\n\nThe investigators will conduct a randomized, crossover, dose-response feeding trial involving 16 generally healthy adult participants (8 females, 8 males). The trial will include four 7-day diet periods, each separated by a 1-week washout. All diets will be based on a dairy-free background and supplemented with one of the following: (a) 1 serving of soy-based pudding (no yogurt), (b) 0.5 serving of yogurt, (c) 1 serving of yogurt, or (d) 2 servings of yogurt per 2,380 kcal\u002Fday.\n\nOn the 7th day of each diet, participants will complete a mixed-meal test at INAF, consuming a smoothie containing the same yogurt dose as during the preceding days. Plasma samples collected in the postprandial state will be used to profile over 20,000 metabolites. Using artificial intelligence-based approaches, potential biomarkers of yogurt intake will be identified. These candidates will then be filtered using standard statistical methods to assess dose- and time-responsiveness, robustness, and biological plausibility. Biomarkers that meet all criteria will be considered validated indicators of yogurt intake.",[232],"Diet",[234,235],"yogurt","biomarker of food intake","2026-03-27",{"date":238,"type":41},"2026-04-02",{"date":240,"type":22},"2026-03-23",{"date":242,"type":22},"2026-06-30",{"name":46,"class":47},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":264,"locationsCount":48},"100630219","evaluation-of-acid-base-disorders-and-ventilation-settings-in-cardiogenic-shock-and-post-cardiac-arrest-patients-comparison-with-ventilo-algorithm-100630219","NCT07484828","Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm","VentilO CU","Inclusion Criteria:\n\n* Adult (Age \\>=18 years old)\n* Under mechanical ventilation with endotracheal tube for :\n\npost cardiac arrest or cardiogenic shock\n\n\\- Bood gases result availability up to 4 hours after coronary unit admission\n\nExclusion Criteria:\n\n* Lack of patient anthropometric data (height and weight) available in the patient record\n* No information in the record regarding the data on the humidification systems used at the time of the first blood gas test upon admission to the coronary care unit.\n* Patient stabilzed in other hospital before coronary unit admission or adjustment of respiratory parameters after a blood gas test.",{"count":252,"type":22},100,"This study aims to better understand how mechanical ventilation settings affect patients admitted to the coronary care unit after cardiac arrest or with cardiogenic shock. These patients often require mechanical ventilation, but current guidelines provide limited evidence on the best approach. Improper ventilation settings can lead to acid-base imbalances, such as respiratory acidosis or alkalosis, which may worsen patient outcomes.\n\nThe retrospective analysis will include 100 adult patients (50 post-cardiac arrest and 50 with cardiogenic shock) who were mechanically ventilated upon admission. The study has two main objectives:\n\nDetermine how often acid-base disorders occur in these patients and describe their characteristics.\n\nCompare the initial ventilator settings chosen by clinicians with those suggested by VentilO, a decision-support algorithm.\n\nThe investigators will evaluate the potential effect of the VentilO recommendations on the first arterial (or capillary) blood gases compared to the real settings.\n\nThis information will help refine the algorithm and guide future research on improving ventilation strategies for critically ill cardiac patients.\n\nParticipation does not involve any intervention, as the study uses existing medical records.",[255,256,156,257],"Cardiac Arrest (CA)","Cardiogenic Shock","Acid Base Disorder","2026-03-18",{"date":260,"type":41},"2026-03-20",{"date":160,"type":22},{"date":263,"type":22},"2026-12",{"name":46,"class":47},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":48},"100605875","comparison-of-two-spo2-targets-with-two-different-oximeters---impact-on-fio2-during-nasal-high-flow-oxygen-therapy-100605875","NCT07168213","Comparison of Two SpO2 Targets With Two Different Oximeters - Impact on FiO2 During Nasal High Flow Oxygen Therapy","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Admiitted in intensive care unit\n* Presence of an arterial catheter\n* Ongoing on high flow nasal oxygen therapy with SpO2 between 88 and 100% with a FiO2 between 40 and 80% with the usual oximeter .\n\nExclusion Criteria:\n\n* No SpO2 signal with oximeter in use\n* False nails or nail polish\n* Methemoglobinemia \\>0.015 on last available arterial gas\n* Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...)\n* Expected to use another respiratory support within two hour of inclusion (NIV or mechanical ventilation)",{"count":120,"type":22},[25],"Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.",[275,276,277,278],"Oxygen Delivery","Acute Respiratory Failure","High Flow Oxygen Therapy","Hypoxemic Acute Respiratory Failure","2026-03-05",{"date":281,"type":41},"2026-03-09",{"date":283,"type":41},"2025-10-21",{"date":285,"type":22},"2027-12",{"name":46,"class":47},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":172,"sex":18,"minAge":117,"maxAge":226,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":48},"100628378","effects-of-cranberry-on-gut-and-metabolic-health-100628378","NCT07460856","Effects of Cranberry on Gut and Metabolic Health","CRANOS","Inclusion Criteria:\n\n* body mass index between 25 and 40 kg\u002Fm2\n* at least one of the following criteria: fasting plasma insulin \\>60 pmol\u002FL, fasting glycemia between 5.5 and 6.9 mmol\u002FL, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and\u002For fasting triglyceride \\>1.35 mmol\u002FL.\n\nExclusion Criteria:\n\n* to have aversion to cranberry products\n* regularly drinking alcohol (\\>2 glasses\u002Fday)\n* having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions\n* taking medication which may affect the study outcomes (i.e. antidiabetic and\u002For cholesterol or lipid-lowering medications and\u002For glucocorticosteroid in supraphysiological doses and\u002For anti-obesity medications)\n* taking regular probiotics and prebiotics (including fruit\u002Fberry polyphenol supplements) in the past 3 months\n* having eating disorders\n* had undergone major surgery 3 months prior to the study or if they had one planned\n* if they had intestinal malabsorption, cirrhosis or chronic kidney disease\n* being pregnant, planning a pregnancy, or breastfeeding.",{"count":295,"type":22},73,[25],"The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.\n\nThe primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.\n\nThis randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.",[299,300,301,302],"Overweight\u002FObesity","Metabolic Syndrome","Insulin Resistance","Microbiota","2026-03-04",{"date":305,"type":41},"2026-03-10",{"date":307,"type":41},"2025-07-07",{"date":263,"type":22},{"name":46,"class":47},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":317,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":332},"100536176","effects-of-a-supervised-rehabilitation-program-on-disease-severity-in-spastic-ataxias-100536176","NCT06261424","Effects of a Supervised Rehabilitation Program on Disease Severity in Spastic Ataxias","IMPACT, a Supervised Rehabilitation Program for Spastic Ataxias: A Rater-blinded, Randomized Controlled Trial","Inclusion Criteria:\n\n* have a confirmed genetic diagnosis of ARSACS or SPG7\n* be able to maintain standing position and to transfert\n* be authorized by their treating neurologist\n* speak French or English\n* be able to give informed consent.\n\nExclusion Criteria:\n\n* have active participation in a rehabilitation program (self-reported information)\n* have another condition causing physical limitations\n* be uncomfortable in a swimming pool\n* be pregnant.","16 Years",{"count":319,"type":22},84,[25],"Spastic ataxias are a group of diseases causing symptoms such as walking difficulties and balance impairments that lead to a high risk of falls. No pharmacological treatments exist to treat these diseases. Unfortunately, little effort is made to develop non-pharmacological treatments specific to spastic ataxias despite the detrimental impact of the disease on several aspects of an individual's life and the high cost of falls for society each year. The three objectives of this project are: 1) to determine the effect of a 12-week rehabilitation program on disease severity as compared with usual care for individuals with spastic ataxias; 2) to identify which factors can help (or not) the implementation of the program in the clinical settings (\"reel world\"); and 3) to explore the cost-benefits of IMPACT \\[rehabIlitation prograM for sPAstiC aTaxias\\]. The team has developed the program to specifically target symptoms present in these patients and was previously pilot-tested. Based on the results obtained in this pilot project, positive effects are expected concerning the disease severity of participants. The investigators want, with this project, provide to health care professionals an option to offer better-suited services to people living with spastic ataxia worldwide.",[323,324],"Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Spastic Paraplegia 7","2026-02-13",{"date":327,"type":41},"2026-02-18",{"date":329,"type":41},"2024-02-01",{"date":108,"type":22},{"name":46,"class":47},5,{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":48},"100625287","measurement-of-expiratory-gas-temperature-in-intubated-patients-to-estimate-expiratory-absolute-humidity-100625287","NCT07420673","Measurement of Expiratory Gas Temperature in Intubated Patients to Estimate Expiratory Absolute Humidity","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Intubated and mechanically ventilated in the intensive care unite\n* Using passive humidification (Heat and Moisture exchanger)\n\nExclusion Criteria:\n\n* PEEP set \\\u003C 12 cmH₂O\n* Inhaled nitric oxide therapy\n* Tracheostomy",{"count":202,"type":22},"Adequate humidification is essential for intubated patients because dry medical gases can cause thick secretions and dangerous endotracheal tube blockages. A clear correlation exists between exhaled and inhaled humidity delivered by heat and moisture exchanger. The objective of this study is to measure the temperature of exhaled gases in intubated patients in order to accurately calculate the absolute humidity during the expiratory phase. These data will allow for a more accurate reproduction of real clinical conditions during bench testing and will improve the assessment of heat and moisture exchanger performance device evaluation.",[342],"Mechanical Ventilator Care",[344,345],"humidification","Passive humidification","2026-02-12",{"date":348,"type":41},"2026-02-19",{"date":350,"type":22},"2026-04",{"date":352,"type":22},"2027-06",{"name":46,"class":47},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":226,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":48},"100624453","incretin-based-therapies-nutrition-and-physical-activity-100624453","NCT07409831","Incretin-based Therapies, Nutrition, and Physical Activity","Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle","HARMONY","Inclusion Criteria:\n\n* Adults aged 18 to 70 years\n* Prescribed, but not yet initiated, incretin-based pharmacotherapy \\[e.g., GLP-1 receptor agonist or dual GIP\u002FGLP1 agonist\\] living with obesity, defined as:\n\n  * BMI \\>30 kg\u002Fm2, or\n  * BMI \\>27 kg\u002Fm2 with presence of comorbidities (e.g., type II diabetes, hypertension, hypercholesterolemia)\n\nExclusion Criteria:\n\n* Medical contraindications to physical activity practice (e.g., unstable cardiovascular disease, severe orthopedic limitation)\n* Prior or ongoing incretin-based therapy or history of bariatric surgery\n* Pregnancy, current breastfeeding or planned pregnancy during the study period\n* Implemented medical devices (e.g. pacemaker, defibrillator)\n* Chronic conditions affecting protein metabolism or nutrition (e.g., advanced kidney disease, active cancer)",{"count":363,"type":22},120,[25],"The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and physical function in adults living with obesity, compared with medication alone, and to assess the feasibility of a collaborative hospital-community care model.\n\nThis one-year pilot study will recruit 120 adults aged 18-70 years with obesity (BMI ≥30 kg\u002Fm² or ≥27 kg\u002Fm² with at least one comorbidity) receiving routine obesity care at the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval. All participants will initiate physician-prescribed incretin-based therapy as part of standard care. The intervention group will receive medication plus a six-month structured lifestyle program delivered in collaboration with an exercise facility, including supervised strength-focused exercise and bi-monthly nutrition counseling, followed by a six-month consolidation phase. The control group will receive medication alone. Outcomes will be assessed at baseline and at 3, 6, and 12 months.\n\nParticipants will be randomly assigned in a 1:1 ratio to either the medication-only group or the combined medication and lifestyle intervention group. Participants randomized in the medication only group will receive a personalized consult with both a registered dietician and kinesiologist at the end of the study.",[367,368],"Obesity & Overweight","Cardiometabolic Conditions",[370,371,372,373,374],"Obesity","Incretin-Based Therapies","Physical Activity","Eating Behaviour","Lifestyle Intervention","2026-02-06",{"date":325,"type":41},{"date":378,"type":22},"2026-03",{"date":380,"type":22},"2028-03",{"name":46,"class":47},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":48},"100622720","eating-fruits-and-vegetables-with-pleasure-100622720","NCT07387289","Eating Fruits and Vegetables With Pleasure!","Eating Fruits and Vegetables With Pleasure! A Pilot Randomized Controlled Feasibility and Acceptability Assessment of a Nutritional Intervention Integrating Eating Pleasure to Promote Healthy Eating in Higher-Weight Adults","PLAISIR","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Presenting with higher body weight, defined in this study as a body mass index (BMI) ≥ 30 kg\u002Fm²\n* Fluent in French, as the nutritional intervention is conducted in this language\n* Able to travel to Laval University to take part in the nutritional intervention\n\nExclusion Criteria:\n\n* Current or past diagnosis of an eating disorder (e.g., binge eating disorder, anorexia nervosa, or bulimia nervosa)\n* Pregnant or breastfeeding individuals",{"count":391,"type":22},88,[25],"The objective of this interventional study is to pilot test a newly evidence-based intervention integrating different dimensions of eating pleasure to promote the consumption of fruits et vegetables. The target population for this study is men and women, aged 18-65 years old, living with a higher weight.The main hypothesis is that this newly pleasure-oriented intervention is feasible and acceptable for the target population. Participants will be randomized in two groups, a first group receiving the newly, 12-week pleasure-oriented intervention (intervention group) and a second group receiving no intervention (control group).\n\nParticipants will:\n\n* Complete a battery of online questionnaires at home before and after the 12-week nutritional intervention (both intervention and control groups);\n* For participants assigned to the intervention group only: take part in a 12-week nutritional intervention consisting of 10 group sessions held at Laval University (approximately 2 hours each) and an individual follow-up by phone (30 to 45 minutes). After each session, participants will complete a short questionnaire assessing their appreciation of the session (5 to 10 minutes), as well as a comprehensive appreciation questionnaire at the end of the 12-week intervention (25 to 30 minutes).",[395],"Healthy Eating",[397,398,399,400,401,402],"Fruits","Vegetables","Adults","Higher weight","Nutritional intervention","Feasibility study","2026-01-27",{"date":405,"type":41},"2026-02-04",{"date":407,"type":22},"2026-02",{"date":263,"type":22},{"name":46,"class":47},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":48},"100475480","phase-4-activated-charcoal-in-poisoned-patient---pilot-trial-100475480","NCT05471479","Activated CHARcoal in Poisoned Patient - Pilot Trial","CHARPP (Activated CHARcoal in Poisoned Patient): RCT Pilot Study","CHARPP-Pilot","Inclusion Criteria:\n\n* Adult and pediatric patients who presented to the hospital less than 6h after the ingestion of a potentially toxic dose of a carbo-adsorbable substance (substance adsorbed by activated charcoal ).\n* Patients who can receive the intervention within 6 hours of proven or suspected intoxication\n\nExclusion Criteria:\n\n* Patients requiring or who will likely require another gastro-intestinal decontamination method;\n* Patients who have contraindication to the use of activated charcoal;\n* Patients who ingested a substance with an entero-hepatic circulation requiring multi-dose AC;\n* Patients who have no clinical equipoise for the use of activated charcoal as per the attending physician.",{"count":252,"type":22},[420],"PHASE4","The goal of this clinical pilot trial is to determine the feasibility of the clinical trial. Then the large-scale CHARPP will be conducted in order to determine the efficacity of activated charcoal as a treatment for acute poisoning in a diverse population of both adults and children suspected of ingesting toxic substances that activated charcoal can adsorb. The main questions it aims to answer are:\n\n* Can activated charcoal administered within a specific time frame prevent the progression of toxicity?\n* How does activated charcoal affect the length of stay in the hospital and the intensive care unit? Researchers will compare the intervention arm (receiving activated charcoal) to the control arm (receiving standard supportive care) to see if activated charcoal reduces hospital stay duration, ICU stay and improves overall patient outcomes.\n\nParticipants will:\n\n* Be randomly assigned to either receive activated charcoal or standard supportive care.\n* Undergo assessments using standardized clinical scales such as the Poison Severity Score and, for children, the PELODS score.\n* Have their functional outcomes evaluated, such as the ability to return to their original residence without help and manage personal hygiene tasks independently.\n\nThis structured approach will help clarify the role of activated charcoal in clinical toxicology and inform future treatment protocols.",[423],"Charcoal, Decontamination, Poisoning",[425,426,427,428,429,430,431,432,433],"activated charcoal","decontamination","poisoning","intoxication","toxicity","clinical trial","toxicology","Emergency medicine","PROBE trial",{"date":435,"type":41},"2026-01-29",{"date":437,"type":41},"2025-07-16",{"date":439,"type":22},"2027-02-01",{"name":46,"class":47},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":470},"100592925","combining-brain-stimulation-and-physiotherapy-for-the-management-of-chronic-low-back-pain-100592925","NCT06999772","Combining Brain Stimulation and Physiotherapy for the Management of Chronic Low Back Pain","Combining Non-invasive Brain Stimulation and Physiotherapy to Improve the Management of Chronic Low Back Pain in Veterans","Inclusion Criteria:\n\n* Adults between 18 and 65 years old\n* Military Veterans with non-specific chronic low back pain (\\> 3 months, \\> 50% of the days in the last 6 months)\n* High level of psychosocial factors, scoring ≥4 on the Start Back Screening Tool\n* Functional limitations, scoring ≥ 15% on the Oswestry Disability Index (ODI)\n\nExclusion Criteria:\n\n* Non-musculoskeletal conditions causing low back pain (e.g., neoplasia, fracture)\n* Diagnosis of drug or alcohol abuse\n* Change of drug dosage in the last month for the treatment of pain or mental health\n* Presenting with any specific rTMS-related exclusion criteria such as previous seizure\u002Fconvulsion, cochlear implant, and pregnancy",{"count":449,"type":22},96,[25],"Chronic low back pain (CLBP) is a major health challenge in Canada, leading to substantial disability and socioeconomic burden, particularly among Veterans. In military Veterans, LBP is the most common chronic pain condition. Conventional interventions have limited effectiveness. The refractoriness to interventions suggests that specific CLBP mechanisms may be missed by current treatments, prompting a shift towards psychologically informed approaches which aim to address emotional and cognitive factors alongside biomedical aspects. The integration of these concepts into physiotherapy is called psychologically informed physiotherapy (PiP). Despite promising results of PiP from randomized controlled trials, residual pain and disability often persist in Veterans. Non-invasive brain stimulation, such as repetitive transcranial magnetic stimulation (rTMS), may enhance the effectiveness of PiP by modulating cognition, emotion, and pain. This proposal seeks to determine whether non-invasive brain stimulation can enhance the effects of PiP.",[453],"Chronic Low-back Pain (cLBP)",[455,456,457,458,459,460,461],"Non-invasive brain stimulation","comorbid psychological risk factors","chronic pain","repetitive transcranial magnetic stimulation","physiotherapy","pyschologically-informed","veterans","2026-01-16",{"date":464,"type":41},"2026-01-20",{"date":466,"type":41},"2025-06-11",{"date":468,"type":22},"2027-06-01",{"name":46,"class":47},2,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":48},"100617389","communit1d-a-customized-virtual-peer-support-program-for-people-living-with-type-1-diabetes-in-canada-100617389","NCT07317986","CommuniT1D: A Customized Virtual Peer Support Program For People Living With Type 1 Diabetes In Canada","Inclusion Criteria: Participants in CommuniT1D must be people living with T1D or another rare, insulin-requiring form of diabetes, namely, Latent autoimmune diabetes of adults (LADA), Maturity-Onset Diabetes of the Youth (MODY), or type 3c, which occurs due to an injury to or removal of the pancreas. Loved ones such as a parent, child, spouse, caregiver, or friend of an individual with T1D or other rarer forms of diabetes will also be eligible to participate in CommuniT1D. Participants must be 18 years and older, reside in Canada, and be able to read the consent form in English or French.\n\nExclusion Criteria: Individuals with type 2 diabetes, pre-diabetes, or gestational diabetes and no connection to T1D, LADA, MODY, type 3c, or other rare, insulin-requiring forms of diabetes will not be included in CommuniT1D. Individuals under 18 years old will also be ineligible to participate. As the program grows, we hope to expand to also include adolescents and children, who may need parental consent for them to join, depending on their Canadian province or territory of residence. Should we be able to pursue this option, we will work with institutional research ethics boards to ensure that we welcome participation by youth while also ensuring their safety within CommuniT1D. In such a case, the age restrictions in our eligibility criteria would change.",{"count":478,"type":22},300,[25],"When you live with type 1 diabetes (T1D), it is easy to feel alone. Managing your own T1D or your child's T1D takes constant effort that is invisible to most people. Often, the only people who really understand what you are going through are other people in similar situations, but it's hard to find those people, especially when there are other aspects of your life that might be different from others with T1D. For example, you might have a very young child with T1D, you might be racialized and deal with racism in health care on top of T1D, you might be going through menopause with T1D, you might be aging out of provincial or parental device coverage, you might speak a different language from most people around you with T1D, or any one of many other things that make your situation unique. This project aims to create regular, small online meetings via Zoom or similar technologies to bring together people across Canada who are managing T1D (their own and\u002For their child's) who have other things in common. We will create these small groups that will meet monthly as well as larger monthly webinars covering topics of interest. We will track how people like the groups, how they feel, what they like and don't like, and adjust the program accordingly. This project is led by researchers and others who themselves live with T1D. We believe that this kind of peer support can be extremely helpful to people with T1D and it will provide needed mental health support.",[482],"Type 1 Diabetes (T1D)",[484],"peer support","2025-12-19",{"date":487,"type":41},"2026-01-05",{"date":307,"type":41},{"date":490,"type":22},"2029-07",{"name":46,"class":47},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100617388","a-study-about-patient-decision-aids-designed-to-help-parents-and-guardians-in-canada-make-evidence-informed-values-congruent-decisions-about-screening-children-for-type-1-diabetes-and-follow-up-decisions-100617388","NCT07317973","A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-congruent Decisions About Screening Children for Type 1 Diabetes and Follow-up Decisions.","Patient Decision Aids for Childhood Type 1 Diabetes Screening, Follow-Up, and Enrolment in Trials","Inclusion Criteria:\n\nParticipants must be 18 or older, live in Canada, be able to read and understand either English or French, and be able to use a computer. They must not have uncorrected visual and\u002For hearing impairments, currently have one or more children and be eligible to make a decision about T1D screening for a current (already born) or future (currently expected due to pregnancy) child.\n\nExclusion Criteria:\n\nAll participants who do not complete the visualization of the tools for various reasons (lack of availability, strong emotions, internet connection problems, etc.) will be excluded from the study.",{"count":500,"type":22},350,[25],"This study will design and test patient decision aids to help parents and guardians in Canada make decisions about screening their children for type 1 diabetes. To do this, we will work with a panel of parents and guardians as well as scientific experts, show draft designs to parents and guardians, improve the draft designs based on feedback, and finally test the patient decision aids in online studies.",[504],"Diabetes, Mellitus, Type 1",{"date":487,"type":41},{"date":507,"type":22},"2026-02-01",{"date":509,"type":22},"2028-04-30",{"name":46,"class":47},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":533,"locationsCount":48},"100615492","optimizing-the-use-of-virtual-reality-in-rehabilitation-for-individuals-with-persistent-shoulder-pain-100615492","NCT07293312","Optimizing the Use of Virtual Reality in Rehabilitation for Individuals With Persistent Shoulder Pain","Optimizing the Use of Virtual Reality in Rehabilitation for Individuals With Persistent Rotator Cuff-related Shoulder Pain","Inclusion Criteria:\n\n* Rotator cuff-related shoulder pain (screen by phone and then confirmed by the physiotherapist at the initial evaluation: pain over the deltoid and\u002For upper arm region, pain associated with arm movement \\[painful arc of movement\\], and familiar pain reproduced with loading or resisted testing during external rotation of the arm) for at least 6 months\n* Minimum score of 15\u002F100 on the shortened version of the Disabilities of the Arm, Shoulder, and Hand (1.5 times the minimally clinically important difference)\n\nExclusion Criteria:\n\n* Unavailable for the 4 weeks intervention\n* Cannot understand or read French\n* Have a diagnosis of rheumatoid, inflammatory or neurodegenerative diseases\n* Have received a corticosteroid injection or any other type of injection (e.g., platelet-rich plasma, prolotherapy, hyaluronic acid) in the past three months for their current condition\n* Have bilateral shoulder pain\n* Have pain in another upper limb joint\n* Have signs of upper (e.g., bilateral paresthesia, hyperreflexia, or spasticity) or lower (e.g., decreased sensation or strength in dermatomes and myotomes, hypotonia, or hyporeflexia) motor neuron lesions\n* History of shoulder surgery, dislocation, or fracture\n* Presence of severe osteoarthritis, symptomatic acromioclavicular joint pathology, or adhesive capsulitis (defined as restriction of passive glenohumeral movement of at least 30% for two or more directions)\n* Full thickness rotator cuff tear, identified by imaging or clinical tests (lag signs and gross weakness)",{"count":120,"type":22},[25],"The primary objective of this clinical trial is to investigate the effect of a block of four specific virtual reality (VR) exercises on upper limb function, pain, kinesiophobia, and pain catastrophizing in individuals with rotator cuff-related shoulder pain (RCRSP). The secondary objective is to examine participants' tolerability of different VR interventions.\n\nStudy Procedures:\n\nParticipants will:\n\n* Attend a face-to-face assessment to confirm eligibility and receive a standardized pain neurophysiology education session (week 0).\n* Visit the clinic once weekly for four weeks to undergo the VR interventions and review pain education concepts (Weeks 5 to 8).\n* Complete online questionnaires evaluating upper limb function, kinesiophobia, pain, sense of presence, and cybersickness.\n\nInterventions\n\nFour VR interventions will be tested:\n\n* Unimanual distraction task with normal visual feedback\n* Bimanual distraction task with normal visual feedback\n* Unimanual reaching task with augmented visual feedback\n* Unimanual reaching task with diminished visual feedback\n\nFindings will guide clinicians in selecting the most effective VR interventions for shoulder impairment and assess the feasibility of implementing VR in a private physiotherapy clinic for individuals with RCRSP.",[522],"Rotator Cuff Related Shoulder Pain",[524,128,525,526,527],"Musculoskeletal Disorders","Education","Shoulder","chronic pain intervention","2025-12-07",{"date":485,"type":41},{"date":531,"type":22},"2026-01-15",{"date":192,"type":22},{"name":46,"class":47},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":172,"sex":18,"minAge":174,"maxAge":87,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":550,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":48},"100612771","impact-of-dairy-integration-into-canadian-food-guide-on-gut-health-100612771","NCT07257913","Impact of Dairy Integration Into Canadian Food Guide on Gut Health","GutMilk","Inclusion Criteria:\n\n* IMC \\\u003C 45\n* Waist circumference \\> 80 cm (Women) or 94 cm (men)\n\nExclusion Criteria:\n\n* History of diabetes (types 1 and 2), CVD, enteropathy, immune diseases or bariatric surgery\n* Cancer (diagnostic and\u002For treatment) during the last 5 years\n* Antibiotic consumption during the last 3 months\n* Active smoking or cannabis consumption\n* Lactose intolerance or allergy, any allergies to foods given in the intervention phases\n* Irregular defecation patterns\n* Pregnancy\u002Flactation\n* Inability to speak French",{"count":542,"type":22},20,[25],"The primary objective is to investigate the impact of milk, fermented milk, and soy beverages, incorporated in a diet reflecting adherence to Canadian food guide recommendations on food choices on gut microbiota in middle-aged adults (45-65 years) with abdominal obesity and slightly deteriorated lipids and\u002For glucose profile. The study aims to discern whether the integration of soy beverages (control), milk, and fermented milk within the CFG diet contributes to distinct gut outcomes and alterations in gut health. We hypothesized that milk and fermented milk will further promote beneficial changes in gut health parameters including gut microbiota composition, trans-epithelial permeability, and inflammation, relative to soy beverages.",[546,547,548,549],"Gut Epithelial Permeability","Gut Microbiota Composition and Diversity","Gut and Circulating Inflammatory Markers","Milk and Digestion",[551,552,553,554],"Milk consumption","Gut epithelial permeability","Inflammation","Gut microbiota","2025-12-01",{"date":557,"type":41},"2025-12-02",{"date":559,"type":41},"2025-10-06",{"date":561,"type":22},"2026-08-31",{"name":46,"class":47},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":48},"100457916","management-of-sleeve-gastrectomy-failure-using-single-anastomosis-metabolic-surgery-100457916","NCT05242835","Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery","Inclusion Criteria:\n\n* had sleeve gastrectomy a minimum of 18 months before\n* still meet the NIH criteria for bariatric surgery (BMI≥35kg\u002Fm2 with major comorbidities or BMI≥40kg\u002Fm2) or patients with EWL\\\u003C50% or significant weight regain (≥20%EWL)\n\nExclusion Criteria:\n\n* general contra-indication for bariatric surgery\n* BMI\\\u003C35kg\u002Fm2\n* pregnancy\n* cirrhosis\n* abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease",{"count":570,"type":22},151,[25],"Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.\n\nResearch Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.\n\nWith the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.",[370,574],"Obesity, Morbid",[576],"Bariatric surgery",{"date":578,"type":41},"2025-12-08",{"date":580,"type":41},"2023-02-03",{"date":108,"type":22},{"name":46,"class":47},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":590,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":48},"100239121","surgery-versus-best-medical-management-for-the-long-term-remission-of-type-2-diabetes-and-related-diseases-remission-100239121","NCT02390973","Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)","REMISSION","Inclusion Criteria:\n\n* BMI ≥ 35\n* type 2 diabetes\n* HbA1c ≥ 6,5 % or fasting glycemia ≥7mmol\u002Fl or non-fasting glycemia ≥11mmol\u002Fl\n* able to consent\n\nExclusion Criteria:\n\n* pregnancy\n* past esophageal, gastric or bariatric surgery\n* irritable bowel, unexplained intermittent vomiting, severe abdominal pain, chronic diarrhea or constipation\n* history of gastric or duodenal ulcers\n* pre-operatory hypoalbuminemy\n* history of renal, hepatic, cardiac or pulmonary severe disease\n* taken of corticosteroid in the last month\n* evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations\n* history of drug use or alcool abuse in the last 12 months\n* history of gastro-intestinal inflammatory diseases",{"count":591,"type":22},408,[25],"Bariatric surgery procedures induce weight loss through restriction and\u002For malabsorption. The mechanisms underlying type 2 diabetes remission and others metabolic improvements after Roux-en-Y Gastric Bypass (RYGB), sleeve gastrectomy (SG) or biliopancreatic diversion with duodenal switch (BPD-DS) have not yet been formally studied. The investigators propose a longitudinal study with the overall objective of measuring the long-term impact of these three bariatric surgeries (RYGB, SG, BPD-DS) on metabolic, renal and cardiovascular fate in patients with type 2 diabetes. The investigators overall hypothesis is that some bariatric procedures generate hitherto unrecognized effects on many disease-related outcomes, which greatly contributes to their beneficial impact in diabetic patients. The investigators propose 3 specific aims: 1) to establish the long term effect of the three surgeries on the metabolic recovery and quality of life in groups of diabetic patients treated with insulin, hypoglycemic agents or diet; 2) to establish the long term impact of the three surgeries on renal and cardiovascular functions in subgroup of patients with these conditions; 3) to compare metabolic impact of surgeries to those of best medical care for diabetes in a non-surgical control group. For most severely obese patients, lifestyle interventions, perhaps effective in inducing short-lived weight losses, are ineffective for long-term weight loss maintenance and durable metabolic recovery. The increasing popularity of obesity surgeries calls for a better understanding of the underlying mechanisms. This is especially true and urgent when considering that knowledge on the relative impact of each procedure (i.e. SG vs. RYGB and BPD-DS) in resolving T2D is still limited. Better knowledge on each of the procedures will allow stronger scientific rationale for selecting the right surgery for the right patient and improve care for the severely obese individual.",[595,596],"Bariatric Surgery Candidate","Diabetes",{"date":578,"type":41},{"date":599,"type":4},"2015-03",{"date":601,"type":22},"2030-03",{"name":46,"class":47},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":613,"briefSummary":614,"conditions":615,"keywords":623,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":48},"100608462","digital-preparation-for-bariatric-surgery-feasability-pilot-trial-100608462","NCT07201870","Digital Preparation for Bariatric Surgery: Feasability Pilot Trial","A Pilot Feasibility Study of the Implementation, Usability, Acceptability and Effectiveness of an Online Bariatric Surgery Preparation Platform","Pilot Be-Ready","Inclusion Criteria:\n\n* Be on the waiting list for metabolic and bariatric surgery at IUCPQ\n* not yet assessed by the local team and with an expected wait time of more than 6 months\n* understand French\n* Have an active email address\n\nExclusion Criteria:\n\n* Be part of the same household as someone already involved in this research project",{"count":612,"type":22},1050,[25],"Metabolic and bariatric surgery (MBS) is in increasing demand due to the growing prevalence of severe obesity and the cumulating evidence of long-term benefits on weight loss, cardiometabolic and functional health outcomes, and quality of life for individuals living with severe obesity. The time spent on the waiting list for an MBS follow the same trend with an estimated waiting time of more than 18 months and rising. The lack of resources and multidisciplinary capabilities among MBS centers impacts the quality of care and outcomes, which greatly contributes to delayed surgery. In 2023, 31% of patients who had an initial appointment with the MBS nurse at the Quebec Heart and Lung Institute - Laval University(IUCPQ) did not proceed with the surgery due to fear, uncertainty, or timing issues. Additionally, 49% reported that their concerns (e.g., financial, home support) were not addressed before MBS. These data highlight the urgent need to implement strategies to optimize wait time and ensure that MBS preparation is tailored to patients' expectations. Telehealth has significantly impacted surgical preparation, including for MBS, by enhancing accessibility, reducing dropout rates, and maintaining clinical outcomes that are comparable to traditional in-person visits but it requires real-time multidisciplinary execution, limiting the applicability for MBS waiting list patients. An interesting complement to telehealth intervention is online education platforms which offer digital flexibility, a significant advantage over in-person session.\n\nTo date, most MBS online resources are fee-based or driven by commercial interests and lack of clinical evidence, which raises concerns about their efficacy and safety for users who are seeking reliable support during their MBS journey.\n\nA free online education platform could optimize the time spent on the MBS waiting list by increasing patients' readiness for MBS, furnishing invaluable insights into the patient journey to MBS, and empowering individuals undergoing MBS. The IUCPQ is in the process of working on the care trajectory of patients with obesity. The Healthcare Direction and the Bariatric Surgery Clinic decided to use a platform called Precare. This platform offers personalized educational content as well as a calendar and appointment management system. It has been accredited by the Quebec Ministry of Health and Social Services. The present research focuses on the pilot testing the implementation and effectiveness of the PreCare solution for patients awaiting bariatric surgery at the IUCPQ.\n\nThe objectives of the research proposal are: 1) To assess the usability and acceptability of the Precare platform using a mixed design methodology; 2) To evaluate the logistical feasibility of using the platform in a clinical setting; 3) To determine whether extensive self-questionnaire assessments may impact the use of the Precare platform; 4) To explore barriers and facilitators to enhance patient engagement and knowledge retention; and 5) To derive estimates variables related to gender, ethnicity, cultural background, learners and psychological profiles for future phases.\n\nOur hypotheses are:\n\n1. The Precare platform will exhibit high usability and acceptability.\n2. Testing the Precare platform in real clinical settings is viable and will yield promising results for improving patient readiness for Metabolic and Bariatric Surgery.",[370,616,617,618,619,620,621,622],"Bariatric Surgery Patients","Online Education","eHealth Literacy","Online-Intervention","Usability Satisfaction","Implementation Strategies","Shared Decision Making",[624,625,626,627],"obesity","bariatric surgery","preparation","education platform","2025-09-23",{"date":630,"type":41},"2025-10-01",{"date":632,"type":22},"2025-10-15",{"date":634,"type":22},"2028-10-01",{"name":46,"class":47},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":646,"briefSummary":647,"conditions":648,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":657,"locationsCount":48},"100579630","ventilo-prospective-study-100579630","NCT06826794","VentilO Prospective Study","Frequency of Respiratory Acidosis in the Intensive Care Unit After Postoperative Cardiac Surgery. Impact of Using VentilO Application","VentilO","Inclusion Criteria:\n\n* Adults (\\> 18 years old)\n* Intubated patients admitted to intensive care immediately post-operatively after cardiac surgery (all cardiac surgery combined)\n* Ventilation in controlled mode (Assist Control or SIMV)\n\nExclusion Criteria:\n\n* Absence of anthropometric data (height and weight) of patients available in the patient file\n* Respiratory cycles mainly spontaneous on arrival\n* Patient extubated on arrival in intensive care",{"count":645,"type":22},76,[25],"This is a randomized, open-label study comparing intial settings made by clinicians with settings recommandation made by the VentilO application immediately after intensive care unit admission.The study will allow direct comparison of the frequency of acidosis when patients are ventilated using the parameters of the VentilO application versus parameters chosen by the clinician. The variables determined by the clinician or VentilO will be respiratory rate, tidal volume and resulting minute ventilation.",[649,650],"Mechanical Ventilation Complication","Respiratory Acidosis","2025-08-27",{"date":653,"type":41},"2025-09-04",{"date":655,"type":41},"2025-04-24",{"date":352,"type":22},{"name":46,"class":47},""]